Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY

Fig. 1

a Distribution of the estimated glomerular filtration rates of the treated men according to the classic or non-classic phenotype (linear regression, p < 0.001); b Risk of renal transplantation according to the phenotype (log-rank test, hazard ratio (HR) classic phenotype = 7.9, p = 0.005); c Prevalence of hypertrophic cardiomyopathy (HCM; log-rank test, median survival HCM-free 46.3 y in classic patients vs 59.1 y in non-classic patients, HR = 3.96, p = 0.02); d Antibody titers according to the chronology of the specific treatment received (A: agalsidase alfa; B: agalsidase beta, mig: migalastat). Complete cross reactivity against agalsidase alfa and beta observed for anti-agalsidase antibodies

Back to article page
\